Yazar "Er, Zehra" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation(Akad Doktorlar Yayinevi, 2016) Korkmaz, Levent; Artac, Mehmet; Karaagac, Mustafa; Er, Zehra; Boruban, Melih C.; Poyraz, Necdet; Kaya, Bugra[Abstract Not Availabe]Öğe Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation(2016) Korkmaz, Levent; Artaç, Mehmet; Karaagaç, Mustafa; Er, Zehra; Boruban, Melih C; Poyraz, Necdet; Kaya, Buğra; Tavlı, Lema; Ödev, KemalÖğe Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab(Springer, 2017) Artac, Mehmet; Uysal, Mukremin; Karaagac, Mustafa; Korkmaz, Levent; Er, Zehra; Guler, Tunc; Boruban, Melih CemPurpose Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach. Hence, there is a strong need for identifying new prognostic factors to show the efficacy of FOLFIRI-bev. Methods This is a retrospective study including patients (n = 90) with mCRC from two centers in Turkey. Neutrophil/lymphocyte (N/L) ratio, platelet count, albumin, and Creactive protein (CRP) were recorded before FOLFIRI-bev therapy. The efficacy of these factors on progression-free survival (PFS) was analyzed with Kaplan Meier and Cox regression analysis. And the cutoff value of N/L ratio was analyzed with ROC analysis. Results The median age was 56 years (range 21-80). Forty-seven percent of patients with N/L ratio >2.5 showed progressive disease versus 43 % in patients with N/L ratio <2.5 (p = 0.025). The median PFS was 8.1 months for the patients with N/L ratio >2.5 versus 13.5 months for the patients with N/L ratio <2.5 (p = 0.025). At univariate Cox regression analysis, high baseline neutrophil count, LDH, N/L ratio, and CRP were all significantly associated with poor prognosis. At multivariate Cox regression analysis, CRP was confirmed to be a better independent prognostic factor. CRP variable was divided into above the upper limit of normal (ULN) and normal value. The median PFSs of the patients with normal and above ULN were 11.3 versus 5.8 months, respectively (p = 0.022). Conclusions CRP and N/L ratio are potential predictors for advanced mCRC treated with FOLFIRI-bev.Öğe Survivin Expression May Affect The Neoadjuvantchemotherapy Response İn Breast Cancer Patients(2017) Er, Zehra; Peştereli, Hatice Elif; Tavlı, Lema; Bozcuk, Hakan; Erdoğan, Gülgün; Esen, Hacı Hasan; Artaç, Mehmet; Korkmaz, Levent; Gündüz, Şeyda; Karaağaç, Mustafa; Demircioğlu, SinanTo investigate whether there is a predictive effect of NF-kappaB, survivin, and Ki-67 expressions on pathological response and disease relapse in breast cancer (BC) patients. Ki-67, survivin and NF-kappaB expressions were analyzed in the pathology specimens of breast biopsy before and after neoadjuvant chemotherapy (NeoCT) in BC patients (n52). Event -free survival (EFS) (defined as recurrence or metastasis free) analyze was performed. The median overall survival was 43.5 months and the median EFS was 51 months (95% CI: 33.3-68.9) in all patients. The expression percentages of NF-kappaB, survivin, and Ki-67 significantly decreased after NeoCT (p>0.001). Survivin expression level before NeoCT was significantly higher in patients who did not respond to NeoCT than both partial-responders and complete-responders (p0.038, p0.010, respectively). Type of NeoCT was the only independent factor on pathological response status (p0.007). Addition of taxanes to NeoCT improved pathological complete response rates about six times. However, no predictor was found to be a prognostic factor for EFS in multivariate analyze. Higher survivin expression level before NeoCT may be associated with poor pathological response to NeoCT. These findings must be tested with prospective clinical trials.
